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Our previous studies have demonstrated that the level of the central transcription factor TATA-binding
protein (TBP) is increased in cells expressing the hepatitis B virus (HBV) X protein through the activation of
the Ras signaling pathway, which serves to enhance both RNA polymerase I and III promoter activities. To
understand the mechanism by which TBP is regulated, we have investigated whether enhanced expression is
modulated at the transcriptional level. Nuclear run-on assays revealed that the HBV X protein increases the
number of active transcription complexes on the TBP gene. In transient-transfection assays with both trans-
formed and primary hepatocytes, the human TBP promoter was shown to be induced by expression of the HBV
X protein in a Ras-dependent manner, requiring both Ral guanine nucleotide dissociation stimulator (Ral-
GDS) and Raf signaling. Transient overexpression of TBP did not affect TBP promoter activity. To further
delineate the downstream Ras-mediated events contributing to TBP promoter regulation in primary rat hepa-
tocytes, the best-characterized Ras effectors, Raf, phosphoinositide 3-kinase (PI-3 kinase), and RalGDS, were
examined. Activation of either Raf or RalGDS, but not that of PI-3 kinase, was sufficient to induce TBP pro-
moter activity. Both Raf- and RalGDS-mediated induction required the activation of mitogen-activated protein
kinase kinase (MEK). In addition, another distinct Ras-activated pathway, which does not require MEK ac-
tivation, appears to induce TBP promoter activity. Analysis of the DNA sequence requirement within the TBP
promoter responsible for these regulatory events defined three distinct regions that modulate the abilities of
Raf, RalGDS, and the Ras-dependent, MEK-independent pathways to regulate human TBP promoter activity.
Together, these results provide new evidence that TBP can be regulated at the transcriptional level and identify
three distinct Ras-activated pathways that modulate this central eukaryotic transcription factor.
The TATA-binding protein (TBP) is a central factor used in
the transcription of all eukaryotic genes (18). TBP is assembled
into at least three distinct protein complexes, SL1, transcrip-
tion factor IID (TFIID), and TFIIIB, by its association with
different TBP-associated factors, which then specifies its role in
the transcription of the RNA polymerase I, II, and III promot-
ers, respectively. In promoters containing a TATA element,
these TBP complexes are recruited through direct interaction
of TBP with the DNA. In contrast, TBP is recruited to pro-
moters that lack a TATA element via protein-protein interac-
tions. The recruitment of TBP to TATA-containing promoters
has been shown to be a rate-limiting step for transcription
activation (for a review, see reference 27). Thus, alterations in
the cellular levels of TBP could produce global changes in
cellular gene activity.
Although the role of TBP in the formation of transcription
initiation complexes has been well studied, little is known re-
garding potential cellular events that might regulate this key
transcription component or its ability to form various TBP-
associated factor-associated complexes. Our previous studies
have demonstrated that expression of the hepatitis B virus
(HBV) X protein in both mammalian and insect cells produces
an increase in the cellular levels of TBP (41). Since the X
protein has been shown to be a promiscuous transcriptional
transactivator, its ability to increase TBP likely contributes to
its effect on a large and diverse number of viral and cellular
promoters. Consistent with this notion, increases in cellular
TBP have been shown to have pronounced effects on cellular
transcription. We have demonstrated that all three classes of
RNA polymerase III-dependent promoters are stimulated in
response to increased levels of TBP, either directly (34) or
indirectly by the expression of the HBV X protein (41) or the
activation of protein kinase C by phorbol ester (13, 14). Evi-
dence supports the idea that this is a result of increased num-
bers of functional TBP-containing TFIIIB complexes at these
promoters (34, 41). The HBV X-dependent increase in TBP
has also been shown to enhance RNA polymerase I-dependent
ribosomal DNA promoters in both insect and mammalian cells
(40). Initial studies that have examined the effect of TBP over-
expression on the transcription of RNA polymerase II-depen-
dent promoters have revealed that, depending on the promoter
architecture, there are different effects. Overexpression of TBP
in Drosophila cells was shown to generally stimulate TATA-
containing promoters to various extents, while TATA-lacking
promoters were either repressed or not affected (8). In mam-
malian cells, overexpression of TBP potentiates the transcrip-
tional activation of certain activators and it represses the acti-
vation of others, depending on the core promoter structure
(16, 31). Thus, the activities of RNA polymerase I- and III-
dependent promoters are enhanced by TBP overexpression
while RNA polymerase II-dependent promoters are differen-
tially regulated.
The HBV X protein is necessary for viral replication in
animal hosts (6, 48), and it has been extensively shown to be a
transcriptional activator (46). X is believed to stimulate gene
activity via two distinct mechanisms dependent on its subcel-
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lular location (9). Many X-responsive RNA polymerase II-
dependent promoters, such as those containing sites for AP-1
and NF-kB, are induced by X through the activation of the
Ras–Raf–mitogen-activated protein (MAP) kinase kinase
(MEK)–MAP kinase (MAPK) and Jun-terminal kinase path-
ways (3, 4, 25). This function of X requires it to be located in
the cytoplasm (9). Our studies have revealed that the X-me-
diated increase in TBP and its ability to induce both the RNA
polymerase I and III promoters are also dependent on the
activation of Ras signaling (39, 40). However, evidence also
supports the idea that X directly interacts with certain tran-
scription components in the nucleus, functioning as a tran-
scriptional coactivator to induce specific cellular promoters
(17, 22, 23, 44). While it is not understood how the transacti-
vation function of X may contribute to the life cycle of the
virus, the importance of the X-mediated activation of cellular
signaling in the HBV replication process was recently demon-
strated (21).
Ras proteins function as critical GDP/GTP-regulated
switches that control cellular signaling from upstream growth
factor receptor tyrosine kinases downstream to a cascade of
serine/threonine kinases. Ras GTPases regulate cellular func-
tion through the activation of multiple signaling pathways me-
diated by distinct effector molecules (20). To date, three effec-
tor molecules that directly interact with Ras have been well
characterized. The Raf serine/threonine protein kinases are
key effectors of Ras that carry signals into the nucleus through
the subsequent activation of MEK and MAPK. In addition to
Raf, other proteins have been characterized that convey Raf-
independent signaling responses. The Ral guanine nucleotide
dissociation stimulator (RalGDS) family of guanine nucleotide
exchange factors directly interacts with Ras (43), stimulating
the GDP/GTP exchange of Ral proteins in a Ras-dependent
manner (35). Ras-mediated cytoskeletal changes are depen-
dent on a pathway involving phosphoinositide 3-kinase (PI-3
kinase) (30). These Ras effector pathways cooperate to exert
the full transforming function of Ras (for a review, see refer-
ence 20). Although much progress has been made in identify-
ing the proteins that are involved in mediating Raf, RalGDS,
and PI-3 kinase signaling, less is known regarding the specific
transcription factors that are ultimately targeted in these re-
sponses or the genes whose expression they regulate.
Our previous studies have identified an important conse-
quence of HBV X-mediated Ras signaling: an increase in the
cellular levels of TBP. Our present studies are the first to
demonstrate that TBP can be regulated transcriptionally. Us-
ing both nuclear run-on assays and transient transfection of the
human TBP promoter into a variety of different cell types, we
show that X modulates TBP at the transcriptional level in a
Ras-dependent manner. The overexpression of TBP does not
appear to regulate TBP promoter activity in a transient-trans-
fection context. We further found that the activation of either
Raf or RalGDS signaling, but not that of PI-3 kinase signaling,
contributes to the X- and Ras-mediated induction of human
TBP (hTBP) promoter activity in primary rat hepatocytes. In-
duction of the hTBP promoter by both Raf and RalGDS re-
quires the activation of MEK. In addition, our results support
the notion that there is another Ras-activated, MEK-indepen-
dent pathway that can stimulate hTBP promoter activity in
hepatocytes. Analysis of DNA sequences within the hTBP pro-
moter also revealed that there are three distinct regions that
confer inducibility of the promoter by these three Ras-acti-
vated signaling events.
MATERIALS AND METHODS
Plasmids. All hTBP promoter-luciferase constructs i.e., p24500/166hTBP-
luc, p21120/166hTBP-luc, p2736/166hTBP-luc, p2176/166hTBP-luc, p284/
166hTBP-luc, p284/21hTBP-luc, and p284/21hTBP-luc-Mets, were the gen-
erous gift of Diane Hawley (12). Mammalian expression plasmids pCMV-X,
pCMV-RasV12, and pCMV-RasA15 were described previously (39). The HBV
X mutant containing a nuclear localization signal, pCMV-X-NLS, was provided
by Robert Schneider (9). TBP expression plasmid pSRa-MSV-LTR-TBP (47)
was provided by Arnold Berk. Thymidine kinase and human b-3 integrin pro-
moter-luciferase constructs (TK-luc and b-3-luc) were described previously (7,
36) and were supplied by Chi Dang. Constitutively activated Ras and Ras effector
mutants, pDCR-RasV12, pDCR-RasV12-S35, pDCR-RasV12-G37, and pDCR-
RasV12-C40 (42), as well as constitutively activated Raf, pcDNA3-Raf-BXB (5,
37), were kindly provided by Michael A. White. Constitutively activated Rlf
(pMT2-HA-Rlf-CAAX) and the Rlf mutant without a catalytic domain, pMT2-
HA-Rlf-DCAT-CAAX (45), were supplied by Hendrick Gille and Johannes Bos.
pCMV-Raf375M has been described previously (32) and was supplied by Jae-
Won Soh. The Ral binding domain mutant (pRK5-RalBD), kindly provided by
Jacques Camonis, is comprised of amino acids 397 to 518 of RLIP76 and was
subcloned from pGEX-4T3-RalBD (2) into expression vector pRK5 using BamHI
and SalI restriction sites. The pBluescript SK1 (pSK) vector DNA was obtained
from Stratagene.
Primary rat hepatocyte preparation and cell culture. Hepatocyte cultures
from male Sprague-Dawley rats (225 to 400 g; 6 to 12 weeks old) were obtained
from the USC Liver Tissue Culture Core Facility. Surgery and isolation were
done as described by Moldeus et al. (24). Cell number and viability (85 to 92%)
were determined by trypan blue exclusion. Cells were initially isolated and
cultured in William’s E medium supplemented with 5% (vol/vol) fetal bovine
serum (FBS), 2 mM L-glutamine, 0.13 ITS-X (insulin at 1 mg/ml, sodium trans-
ferrin at 0.55 mg/ml, 3.9 mM sodium selenite, ethanolamine at 0.2 mg/ml), pen-
icillin at 200 U/ml, streptomycin at 200 mg/ml, amphotericin B (Fungizone) at
0.25 mg/ml, and gentamicin (Life Technologies) at 50 mg/ml. Cells were plated on
Primaria plates (60 by 15 mm; Becton Dickinson) at 106/plate. Human hepato-
blastoma HepG2 and human hepatoma Huh7 cells were propagated in high-
glucose Dulbecco’s modified Eagle medium (Life Technologies) supplemented
with 10% FBS (Summit Biotechnologies, Fort Collins, Colo.), penicillin at 100
U/ml, and streptomycin at 100 mg/ml. All cells were maintained in a saturated,
humidified environment of 5% CO2–95% air at 37°C.
Transient transfections. Transient transfections of HepG2 and Huh7 cells
were performed using a calcium phosphate method (40). For TBP promoter-
luciferase reporter assays, cells were plated in 2 ml of medium per 35-mm well
at a density of 150,000 to 200,000 cells per well on six-well plates. After 24 h, 0.5
mg of the TBP promoter-luciferase construct was transfected with other DNAs as
indicated with a total final DNA amount of 6 mg maintained with pSK. Approx-
imately 16 h later, cells were rinsed well with Dulbecco’s phosphate-buffered
saline (DPBS; Mediatech) and serum starved in high-glucose Dulbecco’s modi-
fied Eagle medium with 0.5% FBS, penicillin at 100 U/ml, and streptomycin at
100 mg/ml for 48 h prior to harvesting.
Primary rat hepatocytes were transfected 4 h after isolation. Hepatocytes were
rinsed well with DPBS and placed in William’s E medium with 2 mM L-glutamine
and 0.13 ITS-X. Cells were transfected with 13.5 mg of total DNA using Lipo-
fectin (Life Technologies; 6.67 mg/mg of DNA) or Targefect F1 (Targeting
Systems; 1 mg/mg of DNA) in accordance with the manufacturer’s specifications.
The TBP promoter-luciferase construct (5.5 mg) was transfected with other
DNAs as indicated, and the total final DNA concentration was maintained with
pSK. To determine the amount of each expression plasmid to use, various
concentrations of each plasmid were initially tested in transfection assays to
identify the minimal amount of DNA that would produce the most nearly
optimal hTBP promoter activity response. While differences in the magnitude of
the effect were observed, in all cases, the overall effect on TBP promoter activity
was the same, irrespective of the amount of plasmid transfected. Cells were
transfected overnight (#14 h), rinsed with DPBS, and placed in William’s E
medium as described above for isolation without serum. Hepatocytes were refed
after 24 h and harvested 48 h following transfection. When appropriate, a final
concentration of 50 mM U0126 (Promega) or 0.5 mM wortmannin (Calbiochem)
or 5 ml of dimethyl sulfoxide vehicle (control) was added to cells for 14 h prior
to hepatocyte harvesting.
Preparation of cell extracts. For the preparation of total cell lysates from
transfected cells for luciferase activity measurements, medium was aspirated
from the cell culture and the cells were gently rinsed with DPBS. Cells were
scraped from the plates and collected by centrifugation. Cell pellets were resus-
pended in Promega reporter lysis buffer. Cell suspensions were lysed by incuba-
tion on ice for 10 min, followed by freezing and thawing of the cell suspension.
Cell lysates were centrifuged for 20 min at 10,000 3 g at 4°C, and the supernatant
was collected for protein and luciferase activity measurements immediately fol-
lowing lysate preparation. Protein concentrations of the resultant cell lysates
were measured by the Bradford method using the Bio-Rad protein assay reagent.
Lysates prepared from transfected cells were analyzed for luciferase activity
using a luminometer and the Promega Luciferase Assay System as described by
the manufacturer (Promega). Resultant luciferase activities were normalized to
the amount of protein in each lysate. For all transient transfections with pro-
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moter-luciferase reporter constructs, the fold change in promoter activity was
calculated by determining the level of luciferase specific activity in the presence
of the empty expression vector DNA or functionally inactive mutant protein
expression plasmid (pMT2-HA-Rlf-DCAT-CAAX only) and setting this value at
1 for each independent experiment. Values are means 6 the standard error of
the mean of at least three independent experiments.
Nuclear run-on transcription assay. Nuclei were isolated as described by
Garber et al. (15). Briefly, cells were washed and resuspended in lysis buffer (10
mM Tris-HCl [pH 8.0], 10 mM MgCl2, 150 mM KCl, 1 mM dithiothreitol)
containing 0.3 M sucrose and 0.1% Nonidet P-40 and homogenized with a
Dounce homogenizer. Nuclei were pelleted at 1,000 3 g, resuspended in lysis
buffer containing 0.25 M sucrose and 10 mg of RNase A, and incubated on ice for
30 min. Nuclei were washed twice in lysis buffer, collected by centrifugation, and
resuspended in 200 ml of reaction buffer (50 mM Tris-HCl [pH 8.0], 150 mM
KCl, 5 mM MgCl2, 0.5 mM MnCl2, 1 mM dithiothreitol, 0.1 mM EDTA, 10%
glycerol, 200 U of RNase inhibitor per ml). For each reaction, 1.6 3 108 nuclei
were used. The in vitro elongation reaction was initiated with the addition of
ribonucleotides to a final concentration of 0.33 mM each ATP, GTP, and CTP
and 100 mCi of [a-32P]UTP (800 Ci/mmol). The reaction was carried out for 10
min at 25°C. Isolation of 32P-labeled RNA, preparation of nitrocellulose filters,
and hybridization reactions were performed as previously described (15). One-
tenth of the labeled nuclear transcripts was hybridized to 10 mg each of the
indicated DNAs immobilized on nitrocellulose to ensure a DNA excess.
RESULTS
The HBV X protein enhances transcription of the endoge-
nous TBP gene in S-2 cells. To begin to examine how the HBV
X protein and oncogenic Ras regulate the cellular levels of
TBP, nuclear run-on assays were carried out to determine
whether TBP is regulated transcriptionally in X-expressing
cells. We previously constructed a Drosophila Schneider S2
stable cell line, X-S2, that expresses X under the control of the
metallothionien promoter (41). As shown in Fig. 1, there was
a significant increase in the number of engaged transcription
complexes on the TBP gene in the X-expressing cells com-
pared to the control cells. As suggested from our previous
studies using transiently transfected genes (39), transcription
from the endogenous copia gene was unaffected. Transcription
of the endogenous U6 RNA gene, an RNA polymerase III
promoter, was substantially enhanced by the expression of X,
consistent with our previous in vitro studies (41). Thus, these
results indicate that at least one mechanism by which X in-
creases cellular TBP is at the level of transcription. Since
previous studies have only examined the effect of X on the
transcription of transiently transfected genes, these results im-
portantly demonstrate that X expression can affect the activity
of endogenous genes as well.
The HBV X protein induces expression of the hTBP pro-
moter in primary and transformed hepatocytes in a Ras-de-
pendent manner. To examine the mechanism by which X reg-
ulates TBP at the transcriptional level, we obtained a plasmid
containing 4.5 kb of the genomic sequence upstream of the
human TBP gene linked to a luciferase reporter (12). To test
whether the human TBP promoter could be regulated by X
and activated Ras, we transiently cotransfected HepG2 and
Huh7 human liver cells with the hTBP promoter-reporter plas-
mid and expression plasmids containing either the X-encoding
gene or a constitutively activated form of Ras, RasV12 (Fig.
2A and B). The expression of either X or activated Ras signif-
icantly stimulated the hTBP promoter in both cell lines. The
X-mediated induction was inhibited by coexpression of a dom-
inant negative form of Ras, RasA15.
Studies have shown that X is largely cytoplasmic and target-
ing it to the nucleus abolishes its ability to stimulate cellular
signaling (9). Expression of a mutant form of X containing a
nuclear localization signal, X-NLS, in HepG2 cells failed to
stimulate the TBP promoter (Fig. 2B), regardless of the
amount of DNA transfected (data not shown). This confirmed
that X exerts its effect in the cytoplasm. To examine whether
the effect of X and Ras on TBP promoter activity is specific to
the transformed phenotype of the cell lines we used, we as-
sessed whether hTBP promoter activity could be similarly reg-
ulated in primary rat hepatocytes. The hTBP promoter was
substantially induced by X, but not by X-NLS, in a Ras-depen-
dent manner (Fig. 2C). Together, these results demonstrate
that X induces the human TBP promoter in both transformed
and nontransformed mammalian hepatocytes by its ability to
activate Ras signaling. Since primary rat hepatocytes represent
a more biologically relevant system and we were able to de-
velop a transient-transfection protocol yielding highly repro-
ducible results, the remaining studies were conducted using
these cells.
Transient overexpression of TBP does not regulate hTBP
promoter activity in primary rat hepatocytes. The results de-
scribed above demonstrate that the X- and Ras-mediated in-
crease in TBP is produced, at least in part, by enhanced tran-
scription. We therefore examined whether overexpression of
TBP could serve to regulate the activity of the TBP pro-
moter. The hTBP promoter was cotransfected with increas-
ing amounts of an hTBP expression plasmid into primary
hepatocytes (Fig. 3). hTBP promoter activity was not affected
at any concentration of the transfected TBP expression plas-
mid used. This can be compared to the thymidine kinase pro-
moter, which was significantly stimulated by overexpression of
TBP, and the human b-3 integrin promoter which, like the
hTBP promoter, was not affected. These results indicate that
the hTBP promoter is not autoregulated by overexpression of
TBP in rat hepatocytes, at least when transiently expressed.
Inhibition of either RalGDS or Raf signaling blocks HBV X
transactivation of the hTBP promoter. In order to begin to
identify the downstream Ras-activated signaling events medi-
ated by X that regulate TBP promoter activity, the contribu-
tions of three well-characterized Ras effectors, PI-3 kinase,
Raf, and RalGDS, were examined. While X has been shown to
activate the Raf-MEK-MAPK pathway, its ability to activate
either PI-3 kinase or RalGDS has not been determined. Hepa-
tocytes were cotransfected with the hTBP promoter construct
and the X expression plasmid and either cotransfected with
dominant interfering mutants or incubated with specific inhib-
itors to prevent signaling from each downstream pathway. As
shown in Fig. 4, incubation of hepatocytes with the PI-3 kinase
inhibitor wortmannin (26) did not affect X induction of the
hTBP promoter. Expression of RafM375, a dominant negative
form of Raf (32), was able to significantly inhibit X-mediated
induction of the hTBP promoter. In addition, the role of MEK,
an immediate downstream target of Raf, was examined. Incu-
bation of hepatocytes with the MEK inhibitor U0126 was
shown to block hTBP promoter induction by X. To determine
the role of RalGDS signaling on X-mediated hTBP promoter
FIG. 1. Nuclear run-on transcription assay comparison of X-expressing and
-nonexpressing Drosophila S-2 cells. Assays were performed as described in
Materials and Methods. Plasmid DNAs used for hybridization contain the gene
for X (HBV X) and the Drosophila genes for TBP, U6 (U6 RNA), and copia.
Equal numbers of nuclei were isolated from X-S2 and S2 cells, and labeled
nuclear transcripts generated from the reactions were hybridized to the desig-
nated plasmid DNAs immobilized on nitrocellulose filters.
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induction, the effect of a Ral binding domain mutant, RalBD,
was analyzed. RalBD contains only the Ral binding domain of
RLIP76, a downstream effector of Ral, and it interacts specif-
ically with the GTP-bound forms of RalA and RalB (2). Thus,
in RalGDS-activated cells, RalBD inhibits RalGDS down-
stream signaling by sequestering activated Ral proteins. Ex-
pression of RalBD significantly reduced X-mediated stimula-
tion of the hTBP promoter. These initial results suggest that
both Raf signaling and RalGDS signaling play important roles
in X-mediated transactivation of the hTBP promoter in pri-
mary rat hepatocytes.
The RalGDS and Raf pathways, but not the PI-3 kinase
pathway, mediate induction of the hTBP promoter through the
activation of MEK. To further elucidate which downstream
Ras-mediated signaling events potentially regulate the hTBP
promoter, three Ras effector loop mutants were used. Each
contains the V12 mutation that renders it constitutively acti-
vated, and in addition, each harbors another distinct mutation
which allows the resultant protein to interact selectively with
one of the three defined downstream Ras targets but not the
other two (20, 43, 45). To determine if the activation of PI-3
FIG. 2. HBV X protein induces hTBP promoter activity through its ability to
activate Ras. The designated cells were transiently cotransfected as described in
Materials and Methods with 0.5 mg (for Huh-7 and HepG2 cells) or 5.5 mg (for
rat hepatocytes) of the TBP promoter-luciferase construct p24500/166hTBP-
luc and one or more of the expression plasmids, as indicated. (A) pCMV-X, X
(4 mg); constitutively activated Ras, RasV12 (0.5 mg); and dominant negative
Ras, RasA15 (1 mg). (B) X (2.75 mg), RasV12 (0.75 mg), RasA15 (1.5 mg), and
X containing a nuclear localizing signal, NLS-X (2.75 mg). (C) X (6 mg), RasV12
(1.7 mg), RasA15 (1.7 mg), and NLS-X (6 mg).
FIG. 3. Transient overexpression of hTBP does not regulate TBP promoter
activity in rat hepatocytes. Primary rat hepatocytes were transiently transfected
with increasing amounts of an hTBP expression plasmid together with 5.5 mg of
a plasmid containing either the TBP promoter, the thymidine kinase promoter,
or the b-3 integrin promoter, each of which was linked to a luciferase reporter.
FIG. 4. Inhibition of Raf or RalGDS signaling blocks activation of the hTBP
promoter by the HBV X protein. Primary rat hepatocytes were transiently
transfected with 5.5 mg of p24500/166hTBP-luc and 6 mg of pCMV-X together
in the presence or absence of the following inhibiting agents: 0.5 mM wortman-
nin, 2 mg of RafM375, 50 mM U0126 (a MEK inhibitor), or 2 mg of RalBD. Cells
treated with U0126 or wortmannin where exposed to inhibitor 14 h prior to
harvesting of the transfected cells.
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kinase could independently induce hTBP promoter activity,
the Ras effector mutant RasV12-C40, which activates PI-3
kinase (30), was cotransfected with the hTBP promoter in
hepatocytes (Fig. 5A). Compared to that of RasV12, expres-
sion of RasV12-C40 did not have any effect on promoter ac-
tivity. In addition, incubation of hepatocytes with the PI-3
kinase inhibitor wortmannin did not inhibit hTBP promoter
activity either in the absence or in the presence of RasV12
expression. To ensure that PI-3 kinase signaling was being
activated or repressed in these cells by the reagents and con-
ditions used, we tested a well-characterized reporter construct
that contains the c-fos promoter, which is known to be regu-
lated by this signaling pathway (19). As shown in Fig. 5B,
RasV12-C40 stimulated c-fos promoter activity and this re-
sponse was effectively blocked by wortmannin. These results
indicate that PI-3 kinase signaling was being regulated in the
hepatocytes and that hTBP promoter activity was unaffected by
either activation or inhibition of PI-3 kinase signaling.
We next ascertained whether the activation of Raf and
RalGDS signaling could contribute to the Ras-mediated hTBP
promoter induction observed. To determine whether activa-
tion of the RalGDS signaling pathway could affect hTBP pro-
moter activity, expression of the Ras effector mutant RasV12-
G37, which interacts with and activates both RalGDS (43) and
the RalGDS-related factor Rlf (45), or expression of a consti-
tutively activated form of Rlf, Rlf-CAAX (45), was examined.
As shown, the expression of either of these proteins produced
a substantial increase in hTBP promoter activity (Fig. 6A).
Analysis of the ability of the Raf signaling pathway to induce
hTBP promoter activity revealed that the expression of either
RasV12-S35, which activates Raf signaling (30), or Raf-BXB,
a constitutively activated form of Raf (5, 37), significantly
enhanced hTBP promoter activity. Thus, the activation of ei-
ther Raf or RalGDS signaling events can serve to regulate
hTBP promoter activity. We further determined the effect on
promoter activity when the two signaling pathways were si-
multaneously activated. Cotransfection of RasV12-G37 and
RasV12-S35 expression plasmids produced an additive effect
on hTBP promoter induction compared to the expression of
FIG. 5. hTBP promoter activity is not regulated by the PI-3 kinase signaling
pathway. Primary rat hepatocytes were transiently transfected with the following
DNAs: A, 5.5 mg of p24500/166hTBP-luc together with 1.7 mg of RasV12 or
RasV12-C40; B, 5.5 mg of c-fos promoter-luc together with 1.7 mg of RasV12 or
RasV12-C40. Wortmannin (0.5 mM) was added where indicated to cells 14 h
prior to harvesting of the transfected cells.
FIG. 6. Both Raf signaling and RalGDS signaling independently stimulate
hTBP promoter activity in a MEK activation-dependent manner. Primary rat
hepatocytes were transiently cotransfected with p24500/166hTBP-luc (5.5 mg)
together with the following DNA(s): A, RasV12 (1.7 mg), RasV12-S35 (1.7 mg),
RafBXB (0.5 mg), RasV12-G37 (1.7 mg), or RasV12-S35 plus RasV12-G37 (0.85
mg of each); B, RasV12 (1.7 mg), RasV12-S35 (1.7 mg), or RasV12-G37 (1.7 mg)
in the presence and absence of RalBD (2 mg). In the left graph in panel B,
promoter activity is compared in the presence and absence of cotransfected
mutant RalBD. Fold change was calculated based on the promoter activity
measured after cotransfection with the empty pRK5 vector alone. For the right
graph, the fold stimulation of promoter activity was calculated by normalizing the
results to the activity of the promoter construct after cotransfection with RalBD.
(C) RasV12 (0.85 mg), RasV12-S35 (1.7 mg), or RasV12-G37 (1.7 mg) in the
presence or absence of 50 mM U0126, a MEK inhibitor. For the left graph,
promoter activity was compared in the presence and absence of 50 mM U0126.
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either one alone. Coexpression of either of these Ras effectors
with RasV12-C40 (which activates PI-3 kinase) did not signif-
icantly change the level of promoter induction (data not
shown). Thus, activation of either the Raf or the RalGDS
pathway is capable of regulating hTBP promoter activity in
primary rat hepatocytes and these pathways work together to
enhance TBP transcription.
The role of RalGDS signaling in hTBP promoter activity
was further analyzed by expressing the Ral binding domain
mutant RalBD to inhibit downstream signaling through Ral.
As shown in Fig. 6B, expression of RalBD significantly reduced
hTBP promoter activity, even in the absence of activated Ras
signaling proteins. This result is consistent with the notion that,
even without expression of the activated signaling proteins,
there is already some activation of the RalGDS pathway within
the hepatocytes that can be blocked by expressing RalBD.
In the presence of RalBD, RasV12-G37-mediated induction
of the promoter was inhibited yet RasV12-S35-mediated in-
duction was not, confirming its selectivity for blocking of
RalGDS signaling. Together, these results demonstrate that
the RalGDS-Ral pathway regulates hTBP promoter activity.
To further explore the signaling pathways involved in Ras-
mediated induction of the hTBP promoter, we determined
whether the activation of MEK is required. The U0126 inhib-
itor was chosen, as it inhibits MEK directly by blocking the
catalytic activity of the active enzyme (11), compared to the
PD098059 inhibitor, which inhibits MEK activation indirectly
by binding to the inactive enzyme, preventing its activation by
Raf (10). As shown in Fig. 6C, incubation of the U0126 inhib-
itor with hepatocytes transfected with the hTBP promoter
alone significantly decreased promoter activity. In addition,
both Raf- and RalGDS-mediated induction of the hTBP pro-
moter was abolished in the presence of the MEK inhibitor.
However, inhibition of MEK activation did not completely
reduce the approximately ninefold hTBP promoter induction
by RasV12 (compare to Fig. 6A). These results indicate that
MEK activation is required for both Raf- and RalGDS-in-
duced stimulation of hTBP promoter activity and support the
idea that there is at least one additional Ras-activated but Raf-
and RalGDS-independent pathway that regulates TBP.
Three distinct regions within the hTBP promoter confer
Ras-mediated inducibility. In order to fully delineate the sig-
naling events, downstream of Ras, that ultimately target spe-
cific transcription components that regulate the human TBP
promoter, we have begun to identify the regions within the
promoter that are important in these Ras-mediated events. A
series of hTBP promoter deletion constructs have been ana-
lyzed (Fig. 7A). The relative activities of the resulting promot-
ers were first compared in the absence of any transfected
signaling proteins to the construct containing 4,500 bp of the
genomic sequence upstream and 66 bp of that downstream of
the translation start site (24500 to 166). The unstimulated
(basal) hTBP promoter activity was essentially maintained
within the sequence including positions 284 to 166 relative to
the translation start site (Fig. 7A). Removal of the 66-bp re-
gion downstream of the start site, which includes a putative Ets
transcription factor binding site, decreased promoter activity
approximately twofold. Additional mutation of a putative Ets
site within the 284 to 21 region reduced transcription approx-
imately 20-fold less than that of the 24500 to 166 construct.
These results are consistent with previous studies conducted
with human HeLa S3 and Namalwa cells, where the minimal
hTBP promoter was also shown to be contained within these
sequences (12).
To determine the sequences necessary for regulation of the
promoter by Ras signaling, the relative abilities of these pro-
FIG. 7. Analysis of sequences required for basal activity and Ras inducibility
of the hTBP promoter. Primary rat hepatocytes were transiently cotransfected
with 5.5 mg of one of the following hTBP promoter constructs: p24500/
166hTBP-luc, p21120/166hTBP-luc, p2172/166hTBP-luc, p284/166hTBP-
luc, p284/11hTBP-luc, p284/11 mETS hTBP-luc, p284/11hTBP-luc-pGL3,
and p284/11mETShTBP-luc-pGL3. (A) The various hTBP promoter constructs
shown were cotransfected with 1.7 mg of the vector alone. Relative basal, un-
stimulated promoter activities were calculated based on the full-length TBP
promoter activity (p24500/166hTBP-luc), which averaged 18.2 6 3.4 U of
luciferase activity/mg of protein. (B) The hTBP promoter constructs were co-
transfected with either 1.7 mg of the vector alone, RasV12, RasV12-S35,
RasV12-C40, or RasV12-G37 as indicated.
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moter constructs to be stimulated with RasV12, RasV12-S35,
RasV12-C40, and RasV12-G37 were compared (Fig. 7B). With
the exception of 21120/166, none of the promoter constructs
tested were stimulated by RasV12-C40, supporting the notion
that PI-3 kinase signaling does not regulate hTBP promoter
activity in these cells. Although it is not clear why the 21120/
166 promoter is induced with RasV12-C40, it is possible that
when the deletion mutant was constructed, a PI-3 kinase-re-
sponsive site was fortuitously created. The ability of RalGDS
activation to stimulate promoter activity required sequences
between 21120 and 2736, as deletion of these sequences sig-
nificantly reduced RasV12-G37 inducibility. Raf inducibility of
the promoter was largely maintained until a putative Ets bind-
ing site at positions 250 to 241 was mutated. These initial
results reveal that this Ets site may be at least one site impor-
tant for Raf-mediated stimulation of the promoter.
RasV12, which activates all downstream pathways, was ca-
pable of significantly inducing all of the promoter constructs.
Although mutation of the Ets binding site within the 284 to
21 fragment completely abolished RasV12-S35 inducibility of
the TBP promoter, RasV12 was still capable of stimulating
promoter activity. These results, together with the results de-
scribed above, provide further evidence that there is a separate
Raf- and RalGDS-independent pathway, activated by Ras, that
regulates hTBP promoter activity. Since DNA sequence anal-
ysis of the 284 to 21 region of the promoter did not reveal any
obvious DNA binding sequences that might confer Ras induc-
ibility of this fragment (12), we considered that sequences
within the plasmid might be responsible for conferring the
Raf-, RalGDS-, and MEK-independent response observed. To
address this issue, the 284/21 and the 284/21 mEts frag-
ments were each subcloned into a pGL3 vector. This vector
introduces a polyadenylation sequence upstream from the
genomic fragment that reduces background luciferase expres-
sion caused by nonspecific transcription initiation (Promega).
The resulting constructs were then transiently expressed in
hepatocytes and tested for RasV12 inducibility. As shown in
Fig. 7B (left side), introduction of these fragments into a dif-
ferent vector did not change their response to RasV12. These
results indicate that it is the genomic promoter fragment itself,
rather than the plasmid, which confers RasV12 inducibility.
DISCUSSION
Our studies demonstrate that the central transcription factor
TBP can be regulated transcriptionally. As our previous work
showed that both the HBV X protein and oncogenic Ras
produce increases in cellular TBP (39, 41), our new results
reveal that this is mediated at the transcriptional level. Nuclear
run-on and transient-transfection assays revealed that X ex-
pression induces both the transcription of the endogenous TBP
gene in insect cells and transient expression of the hTBP pro-
moter in primary rat hepatocytes and human liver cell lines.
The increased transcription of the TBP gene by X is dependent
on the activation of Ras signaling. Since the Ras signal trans-
duction pathway is strongly conserved among the yeast, Dro-
sophila, and mammalian systems (1), it is not surprising that
transcriptional regulation of TBP by X-mediated activation of
this signaling pathway occurs in both insect and mammalian
systems. Although we cannot rule out the possibility that there
are other regulatory events that contribute to the increased
expression of TBP observed in X- and oncogenic Ras-express-
ing cells (39, 41), our results support the notion that transcrip-
tional regulation is an important mechanism that controls the
level of cellular TBP.
To determine how the increase in TBP promoter activity is
regulated, we first considered the possibility that increased
expression of TBP could regulate TBP promoter activity. Pre-
vious studies by Zhou et al. (47) provided evidence that TBP
regulates itself. Clonally selected HeLa S3 cell lines were ob-
tained that expressed a stably transfected hTBP cDNA, yet the
endogenous TBP protein levels were down-regulated. How-
ever, in the present study, when the same hTBP cDNA expres-
sion plasmid was transiently overexpressed in hepatocytes, no
significant change in TBP promoter activity was observed.
Therefore, our results do not support the idea that overexpres-
sion of TBP, at least transiently, in primary hepatocytes can
regulate TBP promoter activity. The autoregulation previously
shown may be a result of long-term overexpression of TBP, or
alternatively, the autoregulation may occur at the protein level
rather than at the transcriptional level. Given the fact that
neither the hTBP promoter (12) nor the human b-3 integrin
promoter (36) contains a discernible TATA element, these
results are consistent with the previous study of Colgan and
Manley (8) that revealed that TATA-lacking RNA polymerase
II-dependent promoters are generally unaffected by the tran-
sient overexpression of TBP in Drosophila cells, whereas
TATA-containing promoters are stimulated. Likewise, we
found that the thymidine kinase promoter, a TATA-containing
promoter, is induced when TBP is overexpressed. Thus, the
ability of TBP to differentially affect RNA polymerase II-de-
pendent gene activity when it is overexpressed may be a gen-
eral feature of vertebrate cells.
Our results clearly show that the HBV X protein activates
the TBP promoter through Ras signaling. Initial analysis re-
vealed that this X-mediated response involved both Raf- and
RalGDS-dependent signaling events. These results suggest
that, in addition to the activation of Raf-dependent signaling
(3), X may also regulate RalGDS signaling. Inhibition of PI-3
kinase did not appear to affect promoter inducibility by X. This
result suggests either that the X-mediated activation of Ras
does not confer PI-3 kinase activation or that the PI-3 kinase
pathway does not regulate hTBP promoter activity in primary
rat hepatocytes. To more conclusively analyze these Ras-acti-
vated pathways contributing to hTBP promoter regulation, the
activation of each downstream Ras effector was analyzed for
the ability to induce hTBP promoter activity. These experi-
ments revealed that the activation or inhibition of PI-3 kinase
does not alter TBP promoter activity, indicating that, at least in
primary rat hepatocytes, this pathway does not regulate TBP.
Modulation of the RalGDS pathway was found to substantially
regulate TBP promoter activity independently of the activity of
other Ras effectors. Using two approaches, expression of either
the Ras effector domain mutant RasV12-G37 or a constitu-
tively activated form of a RalGDS-related protein, Rlf, we
found that activation of the RalGDS pathway was able to
induce TBP promoter activity. Furthermore, expression of a
mutant that blocks RalGDS signaling through Ral proteins not
only significantly inhibited promoter activation by RasV12-
G37 but also decreased promoter activity even in the absence
of transfected signaling proteins. Similar results were also ob-
tained using a dominant negative form of RalB (data not
shown). This suggests that the level of endogenous activated
RalGDS signaling proteins is already significant. Together,
these results demonstrate that the RalGDS pathway is in-
volved in the regulation of TBP promoter activity by both X
and oncogenic Ras.
Since the expression of either RasV12-S35 or constitutively
activated Raf was found to be sufficient for induction of TBP
promoter activity, these results support that the activation of
Raf signaling is another important contributor to TBP regula-
tion. This agrees with our previous studies with Drosophila S-2
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cells that showed that TBP levels were significantly increased
when a constitutively activated form of Raf was expressed (39).
Both RalGDS and Raf signaling events require MEK activa-
tion in order to stimulate TBP promoter activity. This is con-
sistent with previous studies in which expression of either
RasV12-S35 or RasV12-G37 in NIH 3T3 cells was shown to
activate MEK2 (42). While these results appear to suggest that
the Raf- and RalGDS-mediated induction of the TBP pro-
moter occurs via overlapping or converging pathways, addi-
tional experimental evidence indicates that they in fact regu-
late TBP promoter activity via distinct signaling pathways.
First, there are at least seven distinct MEK protein family
members that have been identified to date that target unique
sets of downstream signaling proteins (33). The specificity of
the U0126 MEK inhibitor for all of these different MEK mem-
bers is unclear, but at the concentrations used, it has so far
been shown to inhibit both MEK1 and MEK2 (11). Thus, it is
likely that U0126 does not distinguish between the MEK
proteins that are differentially involved in mediating Raf and
RalGDS signaling. In addition, deletion analysis of the TBP
promoter revealed that different regions within the promoter
are required to mediate induction by RalGDS and Raf signal-
ing events. While a gradual loss of Raf inducibility was ob-
served with progressive deletion of sequences between 21120
and 166, the most significant loss of RasV12-S35 induction
was obtained when a putative Ets site was mutated between
positions 284 and 21. In contrast, sequences between posi-
tions 21120 and 2736 are required for RalGDS-dependent
promoter activation. RalGDS-responsive elements have not
yet been identified; however, certain serum response elements
have been shown to confer RalGDS inducibility (29). Exami-
nation of the TBP promoter sequence did not reveal any serum
response element-like elements within this region. Further
studies are in progress to further define the DNA element(s)
and transcription factor(s) responsible for regulating TBP pro-
moter activity through RalGDS signaling.
In addition to the Raf and RalGDS signaling events that
regulate hTBP promoter activity, our data support the idea
that there is at least one other Ras-mediated pathway that also
regulates TBP promoter activity when oncogenic Ras is ex-
pressed. We found that treatment of cells with the MEK in-
hibitor U0126 did not completely reduce the ability of RasV12
to stimulate hTBP promoter activity (Fig. 6C). In contrast,
U0126 was able to completely block X-mediated induction of
the hTBP promoter (Fig. 4). In addition, when we examined
the promoter deletion constructs for inducibility by RasV12
and the Ras effector mutants, we observed that sequences
within 284 to 21 were sufficient to confer RasV12- or Raf-
mediated stimulation of the promoter but not RalGDS induc-
ibility. Mutation of a putative Ets binding site within this region
abolishes Raf inducibility but not RasV12 activation of the
hTBP promoter. We tested the possibility that the vector itself
introduces sequences that might confer RasV12 inducibility.
However, subcloning of the genomic fragment into a modified
vector did not eliminate RasV12 stimulation of the promoter.
In contrast to these results, neither of these constructs was able
to confer X inducibility of the promoter (data not shown).
Together, these results indicate that there is an additional
signaling pathway(s), distinct from those mediated by Raf and
RalGDS, that is activated by RasV12 in hepatocytes, which can
regulate hTBP promoter activity. This pathway, however, does
not appear to be activated by the HBV X protein. Thus, our
studies strongly support the notion that there are at least three
independent Ras-activated pathways that can contribute to
hTBP promoter regulation in primary rat hepatocytes. Both X
and oncogenic Ras can stimulate promoter activity through the
Raf and RalGDS pathways, and an additional RasV12-acti-
vated pathway may also contribute to hTBP promoter regula-
tion. A model that summarizes these results is shown in Fig. 8.
An essential step in the expression of eukaryotic genes is the
assembly of transcription complexes at the promoter. There is
evidence that the recruitment of TBP, which is required for the
transcription of all cellular promoters, is rate limiting for tran-
scription in vivo. TBP is limiting for both the RNA polymerase
I (40) and III (32) promoters, while RNA polymerase II pro-
moters are differentially regulated by the overexpression of
TBP (8, 16, 31; Fig. 3). Thus, mechanisms which regulate the
function and production of TBP can profoundly alter cellular
gene expression. Our previous studies have provided several
lines of evidence that the levels of TBP are up-regulated in the
cellular transformation process. Expression of the HBV X
protein, a transcriptional transactivator that is thought to be an
important contributor to the ability of HBV to transform hepa-
tocytes (46), has been shown to significantly increase cellular
TBP levels in both insect and mammalian cell lines (39). This
increase in TBP is dependent on the ability of X to activate
specific protein kinases (41) and Ras (39). In addition, the
activation of protein kinase C by the tumor-promoting phorbol
ester 12-O-tetradecanoylphorbol-13-acetate also increases cel-
lular TBP levels (13). The relevance of these findings to human
tumorigenesis is supported by results that revealed that TBP
mRNA levels are significantly increased in lung and breast
carcinomas (38). Furthermore, initial studies have revealed
that colon tumor cell lines have substantially increased levels of
TBP compared to nontumor colon epithelial cells (S. S. John-
son and D. L. Johnson, unpublished data). Together, these
studies suggest the intriguing possibility that increases in the
cellular levels of TBP are important in the transformation
process. Our studies will continue to define the molecular
events transmitted from the Ras-activated pathways to the
hTBP promoter that regulate its activity and to discern
FIG. 8. Schematic model for Ras pathway regulation of hTBP promoter
activity in primary rat hepatocytes. The model is based on the data in Fig. 4 to
7. Raf-, and RalGDS-MEK-dependent pathways and at least one MEK-inde-
pendent pathway activate hTBP promoter activity. Three distinct sites within the
TBP promoter further define these distinct Ras signaling events.
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whether the resultant increase in cellular TBP levels contrib-
utes to Ras-mediated transformation.
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